# **HEALTH CARE REFORM**

# Primary Care Utilization and Colorectal Cancer Outcomes Among Medicare Beneficiaries

Jeanne M. Ferrante, MD, MPH; Ellen P. McCarthy, PhD, MPH; Eduardo C. Gonzalez, MD; Ji-Hyun Lee, DrPH; Ren Chen, MD, MPH; Kymia Love-Jackson, MBA; Richard G. Roetzheim, MD, MSPH

**Background:** Primary medical care may improve colorectal cancer (CRC) outcomes through increased use of CRC screening tests and earlier diagnosis. We examined the association between primary care utilization and CRC screening, stage at diagnosis, CRC mortality, and all-cause mortality.

**Methods:** We conducted a retrospective cohort study of patients, aged 67 to 85 years, diagnosed as having CRC between 1994 and 2005 in the Surveillance, Epidemiology, and End Results–Medicare–linked database. Association of the number of visits to primary care physicians (PCPs) in the 3- to 27-month period before the CRC diagnosis and CRC screening, early-stage diagnosis, CRC mortality, and all-cause mortality were examined using multivariable logistic regression and Cox proportional hazards models.

**Results:** The odds of CRC screening and early-stage di-

agnosis increased with increasing number of PCP visits (P < .001 for trend). Compared with persons having 0 or 1 PCP visit, patients with 5 to 10 visits had increased odds of ever receiving CRC screening at least 3 months before diagnosis (adjusted odds ratio, 2.60; 95% CI, 2.48-2.72) and early-stage diagnosis (1.35; 1.29-1.42). Persons with 5 to 10 visits had 16% lower CRC mortality (adjusted hazard ratio [AHR], 0.84; 95% CI, 0.80-0.88) and 6% lower all-cause mortality (0.94; 0.91-0.97) compared with persons with 0 or 1 visit.

**Conclusions:** Medicare beneficiaries with CRC have better outcomes if they have greater utilization of primary care before diagnosis. Revitalization of primary care in the United States may help strengthen the national efforts to reduce the burden of CRC.

Arch Intern Med. 2011;171(19):1747-1757

OLORECTAL CANCER (CRC) is the fourth most common cause of new cancers and second leading cause of cancer deaths in the United States.<sup>1</sup> In 2010, there were an estimated 142 570 incident cases and 51 370 deaths from CRC. The 5-year survival rate is greater than 90% for localized CRC, decreasing to 70% for regional disease and 11% for distant stage.<sup>1</sup> Screening for CRC prevents cancer, detects early-stage cancer, and decreases cancer-related mortality.<sup>2</sup>However, only 59% of American adults aged 50 years or older have ever received a CRC screening test.3 Primary care physicians (PCPs) play a critical role in the delivery of CRC screening by ordering fecal occult blood tests (FOBTs) or referring patients for colon endoscopy. Indeed, a PCP's recommendation is one of the strongest predictors of patients' adherence to CRC screening.4,5

Population-based studies have found that a higher supply of PCPs is associated with lower incidence of CRC,<sup>6,7</sup> earlier CRC stage at diagnosis,<sup>8</sup> and lower mortality.<sup>8</sup> However, these ecologic studies are limited in that it is not possible to determine whether individuals with better outcomes are the same as those who received care from PCPs. Therefore, the effect of PCPs on CRC outcomes and the degree that it affects stage at diagnosis and mortality are unclear. Understanding the potential effects of PCPs on CRC outcomes is also important because of the anticipated shortage of approximately 44 000 adult PCPs by 2025.<sup>9</sup> Current difficulties in accessing primary care by some populations will be further aggravated by the influx of adults needing primary care resulting from expanded national health coverage in the recently enacted health care reform law.<sup>10,11</sup>

# See Invited Commentary at end of article

Medicare serves as a universal health insurance system for 39 million elderly Americans.<sup>12</sup> However, use of PCP services varies substantially among Medicare beneficiaries, with many seeing multiple specialists at the exclusion of PCPs.<sup>13</sup> Not using PCPs may limit opportunities to receive CRC screening and create barriers to achieving national cancer control

Author Affiliations are listed at the end of this article.

goals. Therefore, we examined the association between utilization of PCPs and CRC outcomes in Medicare beneficiaries. We hypothesized that Medicare beneficiaries with few or no visits to a PCP would be more likely to have CRC diagnosed at the advanced stage and have higher mortality and that these differences would be explained by differences in previous receipt of CRC screening, defined as having a CRC screening test at least 3 months before cancer diagnosis.

#### METHODS

# DATA SOURCE AND STUDY SAMPLE

This study used a retrospective cohort of persons diagnosed as having CRC within the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database14 between 1994 and 2005 (N=225 459). We excluded persons having cancers of the anus, anal canal, or anorectum (n=91); persons diagnosed as having CRC on death certificates or at autopsy (n=2269)15; persons diagnosed as having other cancers before or within 1 year after their primary CRC diagnosis (n=1710); and those eligible for Medicare because of end-stage renal disease (n=808). We also excluded persons older than 85 years because CRC screening is not recommended in this age group (n = 14087).<sup>2</sup> To ensure that participants had at least 24 months of Medicare claims before their CRC diagnosis, we excluded those diagnosed as having CRC before age 67 (n=52166). We further excluded individuals enrolled in Medicare health maintenance organizations within 2 years before cancer diagnosis through 1 year after diagnosis (n=42466)because their claims were unavailable. Finally, we excluded patients without continuous Part A and Part B Medicare coverage during this 3-year period (n=28 237). Our final analytic sample included 83 625 persons with CRC. This study was approved by the institutional review boards of the University of South Florida and Beth Israel Deaconess Medical Center.

#### UTILIZATION OF PRIMARY CARE

To assess primary care services, we examined Medicare claims for the following ambulatory-based evaluation and management services: routine office visits (*Current Procedural Terminology*<sup>16-18</sup> [*CPT*] codes 99201-99205, 99211-99215, and 99354-99359), outpatient consultations (99241-99245, 99271-99275, 99301-99303, 99311, and 99312), ambulatory visits outside the home (99313, 99315-99316, 993211-99323, 99311-99333, and 99341-99350), and visits for preventive or administrative care (99387, 99397, 99401-99404, 99411-99412, 99420, 99429-99450, and 99455-99546).

We identified the physician specialty associated with each claim by using the unique physician identification number (UPIN) and the Medicare provider specialty field.<sup>19,20</sup> We defined PCPs as general practice, family medicine, primary care internal medicine, geriatric medicine, and obstetrics/gynecology (OB/GYN). We included OB/GYN as primary care because 64.3% of visits to OB/ GYN practitioners are for routine follow-up or preventive care.<sup>21</sup> Because only 2% of claims were from OB/GYN, there was no change in sensitivity analyses that classified an OB/GYN physician as a non-PCP. We identified 160 629 physician UPINs corresponding to primary care specialties and 198 359 physician UPINs corresponding to non–primary care specialties. In addition, there were 7707 physician UPINs (2.1% of all UPINs) with the specialty designated solely as "multi-specialty clinic or group practice." These were considered non-PCP specialties.

For each participant, we assessed ambulatory care physician claims during the 3- to 27-month period before diagnosis. Because physician visit patterns are likely to change during the time that a potential cancer is being diagnosed, we excluded the 3-month period immediately before diagnosis and assessed physician claims during the 24-month period before this.<sup>22</sup> We assessed visits to PCPs by calculating the total number of ambulatory care claims to PCPs during this period. We created categories of PCP visits corresponding to quartiles (0 or 1, 2-4, 5-10, and  $\geq 11$  visits). Visits to non-PCPs were assessed in a similar fashion.

# STAGE AT DIAGNOSIS AND MORTALITY

Stage at diagnosis was classified using the American Joint Commission on Cancer<sup>23,24</sup> staging system (0, I, II, III, and IV), with early-stage CRC defined as stages 0 and I and late stages defined as II, III, and IV. Because distal CRCs are more susceptible to early detection, we created a variable differentiating proximal lesions (proximal to and including the splenic flexure) and distal lesions (the descending colon through the rectum).<sup>25</sup>

The SEER Program conducts follow-up annually to ascertain vital statistics for all cases. Linkages are made to state vital statistics to obtain the date and underlying cause of death. In all-cause mortality analyses, persons who were alive at the end of follow-up (December 31, 2007) were censored; in CRC mortality, those who died of causes other than CRC were also censored.

# CANCER SCREENING TESTS

As one probable mechanism by which primary care would lead to an earlier stage at diagnosis and a lower CRC mortality, we examined whether the number of PCP visits was associated with ever having CRC screening. We assessed the following CPT<sup>16</sup> codes; International Classification of Diseases, Ninth Revision (ICD-9) codes; and Healthcare Common Procedure Coding System (HCPCS)<sup>26</sup> codes: FOBT (CPT codes 82270 and 82273 and HCPCS code G0107), sigmoidoscopy (CPT codes 45305, 45308, 45309, 45315, 45320, and 45331 and HCPCS code G0104), colonoscopy (CPT codes 45380, 45384, and 45385 HCPCS codes G0105 and G0121), barium enema (CPT codes 74270 and 74280 and HCPCS codes G0106, G0120, and G0122), and office visits for CRC screening (ICD-9 codes V76.51 and V76.41). We included any claim for CRC-related services (FOBT, sigmoidoscopy, colonoscopy, and barium enema) for the full study period, excluding the 3 months before the diagnosis, to better capture receipt of colonoscopies. The mean (SD) time for assessment before CRC screening was 6.7 (3.3) years. Consistent with previous studies of preventive care,<sup>22,27,26</sup> we excluded any CRC screening tests in the 3 months before the diagnosis to exclude tests potentially related to the diagnosis of CRC.

#### STATISTICAL ANALYSIS

The relationship between PCP visits and previous CRC screening was evaluated using multivariable logistic regression. Likewise, we used multivariable logistic regression models to examine the relationship between PCP visits and early-stage diagnosis, excluding persons with unknown stage (n=8049). Odds ratios of early-stage (0 or I) compared with late-stage (II, III, or IV) diagnosis and corresponding 95% CIs were calculated for each category of PCP visits compared with the reference group (0 or 1 visit). To determine whether PCP visits were associated with early-stage diagnosis beyond receipt of previous CRC screening, we fitted logistic models with and without previous CRC screening and examined changes in the estimated odds ratio for PCP visits.

We considered the following potential confounders in multivariable models: number of non-PCP visits, age at diagnosis,

#### Table 1. Characteristics of 83 625 Patients With Colorectal Cancer

Characteristic	No. (%)
PCP visits in previous 3-27 mo	
0 or 1	23 206 (27.8)
2-4	20 407 (24.4)
5-10	19 140 (22.9)
≥11	20 872 (25.0)
Non-PCP visits in previous 3-27 mo	
0 or 1	28 480 (34.1)
2-4	17 480 (20.9)
5-10	16 998 (20.3)
≥11	20 667 (24.7)
Receipt of influenza vaccination in previous 3-27 mo	
No	40 996 (49.0)
Yes	42 629 (51.0)
Age at diagnosis, y	
67-75	40 330 (48.2)
76-85	43 295 (51.8)
Sex	
Male	39 821 (47.6)
Female	43 804 (52.4)
Race/ethnicity	
White, non-Hispanic	69 191 (82.7)
Black, non-Hispanic	6278 (7.5)
Hispanic	3738 (4.5)
Asian/American Indian/Pacific Islander	4268 (5.1)
Other	150 (0.2)
Charlson comorbidity index	
0	47 541 (56.9)
1	19766 (23.6)
≥2	16318 (19.5)
Year of diagnosis	10,400,(00,0)
1994-1997	19429 (23.2)
1998-2000	18 605 (22.3)
2001-2005	45 591 (54.5)
Married including common low	COOF (7 E)
Single never merried	0293 (7.3)
Single, never marneu	44 000 (00.0)
Separateu/uivorceu Widowod	4931 (0.9)
Widowed	23 990 (20.7)
Ulikilowii MSA of regidence (n. 82.622)	3590 (4.5)
VISA OI TESIUEIICE (II = 03 023)	AG 400 (EE E)
Metropolitan	40 423 (33.3) 22 030 (27 A)
Urban	5407 (6 5)
	7253 (8.7)
Unknown	1610 (1.0)
Educational level (n – 80 281)	1010 (1.3)
Ouintile 1 Iowest	15 996 (19 9)
Ouintile 2	15 951 (10 0)
Quintile 3	16 188 (20.2)
Ouintile 4	15 921 (10 8)
Quintile 5 highest	16 225 (20 2)
Guintilo 0, Highlost	10220 (20.2)

 Table 1. Characteristics of 83 625 Patients

 With Colorectal Cancer (continued)

Income level (n = 83 103)         17 224 (20.7)           Quintile 1, lowest         16 591 (20.0)           Quintile 3         16 448 (19.8)           Quintile 4         16 562 (19.9)           Quintile 5, highest         16 278 (19.6)           SEER registry <sup>a</sup> 3615 (4.3)           Connecticut, 1973 +         8085 (9.7)           Detroit, 1973 +         8443 (10.1)           Hawaii, 1973 +         1558 (1.9)           lowa, 1973 +         8663 (10.6)           New Mexico, 1973 +         2182 (2.6)           Seattle, 1974 +         4912 (5.9)           Utah, 1973 +         2292 (2.7)           Atlanta, 1975 +         2700 (3.2)           San Jose, 1988 +         7586 (9.1)           Rural Georgia, 1992 +         268 (0.3)           Greater California, 2000 +         9219 (11.0)           Kentucky, 2000 +         111 76 (13.4)           Unknown         963 (1.2)           Histologic type         4           Adenocarcinoma         82 177 (98.3)           Carcinoid         974 (1.2)           Miscellaneous         474 (0.6)           Stage at diagnosis         0, In situ           O, In situ         6913 (8.3)           I <th>Characteristic</th> <th>No. (%)</th>	Characteristic	No. (%)
Quintile 1, lowest         17 224 (20.7)           Quintile 2         16 591 (20.0)           Quintile 3         16 448 (19.8)           Quintile 5, highest         16 276 (19.6)           SEER registry <sup>a</sup> 5           San Francisco, 1973 +         3615 (4.3)           Connecticut, 1973 +         8085 (9.7)           Detroit, 1973 +         8443 (10.1)           Hawaii, 1973 +         1558 (1.9)           Iowa, 1973 +         8863 (10.6)           New Mexico, 1973 +         2182 (2.6)           Seattle, 1974 +         4912 (5.9)           Utah, 1973 +         2292 (2.7)           Atlanta, 1975 +         2700 (3.2)           San Jose, 1988 +         2164 (2.6)           Los Angeles, 1988 +         2164 (2.6)           Los Angeles, 1988 +         2164 (2.6)           Louisiana, 2000 +         4181 (5.0)           New Jersey, 2000 +         4181 (5.0)           New Jersey, 2000 +         4181 (5.0)           New Jersey, 2000 +         4181 (5.0)           Netogic type         4           Adenocarcinoma         82 177 (98.3)           Carcinoid         974 (1.2)           Miscellaneous         474 (0.6)           Stage at diagn	Income level (n = 83 103)	
Quintile 2         16 591 (20.0)           Quintile 3         16 448 (19.8)           Quintile 4         16 562 (19.9)           Quintile 5, highest         16 278 (19.6)           SEER registry <sup>a</sup> 3615 (4.3)           Connecticut, 1973 +         8085 (9.7)           Detroit, 1973 +         8043 (10.1)           Hawaii, 1973 +         8433 (10.1)           Hawaii, 1973 +         8863 (10.6)           New Mexico, 1973 +         2182 (2.6)           Seattle, 1974 +         4912 (5.9)           Utah, 1973 +         2202 (2.7)           Atlanta, 1975 +         2700 (3.2)           San Jose, 1988 +         2164 (2.6)           Los Angeles, 1988 +         2164 (2.6)           Los Angeles, 1988 +         2164 (5.0)           Louisiana, 2000 +         4181 (5.0)           New Jersey, 2000 +         11 176 (13.4)           Unknown         963 (1.2)           Histologic type         320 (2.3)           Adenocarcinoma         82 177 (98.3)           Carcinoid         974 (1.2)           Miscellaneous         474 (0.6)           Stage at diagnosis         0, In situ           0, In situ         6913 (8.3)           1	Quintile 1, lowest	17 224 (20.7)
Quintile 3       16 448 (19.8)         Quintile 5, highest       16 562 (19.9)         Quintile 5, highest       16 278 (19.6)         SEER registry <sup>a</sup> San Francisco, 1973 +         San Francisco, 1973 +       8615 (4.3)         Connecticut, 1973 +       8085 (9.7)         Detroit, 1973 +       8603 (10.6)         New Mexico, 1973 +       2182 (2.6)         Seattle, 1974 +       4912 (5.9)         Utah, 1973 +       2292 (2.7)         Atlanta, 1975 +       2700 (3.2)         San Jose, 1988 +       2164 (2.6)         Los Angeles, 1988 +       2168 (0.3)         Greater California, 2000 +       9219 (11.0)         Kentucky, 2000 +       11 176 (13.4)         Unknown       963 (1.2)         Histologic type       4         Adenocarcinoma       82 177 (98.3)         Carcinoid       974 (1.2)         Miscellaneous       474 (0.6)         Stage at diagnosis       0, In situ         0, In situ       6913 (8.3)         1       18 624 (22.3)         II       18 389 (22.0)         IV       8622 (10.3)         Unknown       809 (9.6)         Tumor grade       Well differentiated	Quintile 2	16 591 (20.0)
Quintile 4         16 562 (19.9)           Quintile 5, highest         16 278 (19.6)           SEER registry <sup>a</sup> 3615 (4.3)           Connecticut, 1973 +         8085 (9.7)           Detroit, 1973 +         8085 (10.1)           Hawaii, 1973 +         1558 (1.9)           lowa, 1973 +         8863 (10.6)           New Mexico, 1973 +         2182 (2.6)           Seattle, 1974 +         4912 (5.9)           Utah, 1973 +         2292 (2.7)           Atlanta, 1975 +         2700 (3.2)           San Jose, 1988 +         2164 (2.6)           Los Angeles, 1988 +         2164 (2.6)           Los Angeles, 1988 +         268 (0.3)           Greater California, 2000 +         9219 (11.0)           Kentucky, 2000 +         5418 (6.5)           Louisiana, 2000 +         4181 (5.0)           New Jersey, 2000 +         11 176 (13.4)           Unknown         963 (1.2)           Histologic type         Adenocarcinoma           Adenocarcinoma         82 177 (98.3)           Carcinoid         974 (1.2)           Miscellaneous         474 (0.6)           Stage at diagnosis         0, In situ           0, In situ         6913 (8.3)           I	Quintile 3	16 448 (19.8)
Quintile 5, highest         16 278 (19.6)           SEER registry <sup>3</sup> 3615 (4.3)           Connecticut, 1973+         8085 (9.7)           Detroit, 1973+         8443 (10.1)           Hawaii, 1973+         1558 (1.9)           lowa, 1973+         8663 (10.6)           New Mexico, 1973+         2182 (2.6)           Seattle, 1974+         4912 (5.9)           Utah, 1973+         2292 (2.7)           Atlanta, 1975+         2700 (3.2)           San Jose, 1988+         2164 (2.6)           Los Angeles, 1988+         2164 (2.6)           Los Angeles, 1988+         268 (0.3)           Greater California, 2000+         4181 (5.0)           Louisiana, 2000+         4181 (5.0)           Louisiana, 2000+         4181 (5.0)           New Jersey, 2000+         11176 (13.4)           Unknown         963 (1.2)           Histologic type         Adenocarcinoma           Adenocarcinoma         82 177 (98.3)           Carcinoid         974 (1.2)           Miscellaneous         474 (0.6)           Stage at diagnosis         0           0, In situ         6913 (8.3)           1         18 624 (22.3)           II         18 389 (22.0) </td <td>Quintile 4</td> <td>16 562 (19.9)</td>	Quintile 4	16 562 (19.9)
SEER registry <sup>a</sup> 3615 (4.3)         Connecticut, 1973 +       8085 (9.7)         Detroit, 1973 +       8043 (10.1)         Hawaii, 1973 +       1558 (1.9)         Iowa, 1973 +       8863 (10.6)         New Mexico, 1973 +       2182 (2.6)         Seattle, 1974 +       4912 (5.9)         Utah, 1973 +       2292 (2.7)         Atlanta, 1975 +       2700 (3.2)         San Jose, 1988 +       2164 (2.6)         Los Angeles, 1988 +       2164 (2.6)         Los Angeles, 1988 +       2168 (0.1)         Rural Georgia, 1992 +       268 (0.3)         Greater California, 2000 +       9219 (11.0)         Kentucky, 2000 +       11176 (13.4)         Unknown       963 (1.2)         Histologic type       Adenocarcinoma         Adenocarcinoma       82 177 (98.3)         Carcinoid       974 (1.2)         Miscellaneous       474 (0.6)         Stage at diagnosis       0, In situ       6913 (8.3)         I       18 624 (22.3)         III       18 389 (22.0)       IV         Well differentiated       7650 (9.2)         Moderately differentiated       49189 (58.8)         Poorly differentiated       667 (0.8)	Quintile 5, highest	16278 (19.6)
San Francisco, 1973 +       3615 (4.3)         Connecticut, 1973 +       8085 (9.7)         Detroit, 1973 +       1558 (1.9)         Iowa, 1973 +       1558 (1.9)         Iowa, 1973 +       2182 (2.6)         Seattle, 1974 +       4912 (5.9)         Utah, 1973 +       2292 (2.7)         Atlanta, 1975 +       2700 (3.2)         San Jose, 1988 +       2164 (2.6)         Los Angeles, 1988 +       2168 (9.1)         Rural Georgia, 1992 +       268 (0.3)         Greater California, 2000 +       9219 (11.0)         Kentucky, 2000 +       5418 (6.5)         Louisiana, 2000 +       4181 (5.0)         New Jersey, 2000 +       11176 (13.4)         Unknown       963 (1.2)         Histologic type       4denocarcinoma         Adenocarcinoma       82 177 (98.3)         Carcinoid       974 (1.2)         Miscellaneous       474 (0.6)         Stage at diagnosis       0, In situ       6913 (8.3)         I       18 624 (22.3)       11         III       18 829 (22.0)       12 3028 (27.5)         III       18 899 (22.0)       17 (98.9)         IV       8622 (10.3)       18 829 (22.0)         IV	SEER registry <sup>a</sup>	
Connecticut, 1973 +         8085 (9.7)           Detroit, 1973 +         8443 (10.1)           Hawaii, 1973 +         1558 (1.9)           lowa, 1973 +         8863 (10.6)           New Mexico, 1973 +         2182 (2.6)           Seattle, 1974 +         4912 (5.9)           Utah, 1973 +         2292 (2.7)           Atlanta, 1975 +         2700 (3.2)           San Jose, 1988 +         7586 (9.1)           Rural Georgia, 1992 +         268 (0.3)           Greater California, 2000 +         9219 (11.0)           Kentucky, 2000 +         11176 (13.4)           Unknown         963 (1.2)           Histologic type         4           Adenocarcinoma         82 177 (98.3)           Carcinoid         974 (1.2)           Miscellaneous         474 (0.6)           Stage at diagnosis         0, In situ           0, In situ         6913 (8.3)           1         18 624 (22.3)           II         18 839 (22.0)           IV         8622 (10.3)           Unknown         8049 (9.6)           Tumor grade         Well differentiated           Well differentiated         6750 (9.2)           Moderately differentiated         6750 (9.2)	San Francisco, 1973+	3615 (4.3)
Detroit, 1973 +         8443 (10.1)           Hawaii, 1973 +         1558 (1.9)           lowa, 1973 +         8863 (10.6)           New Mexico, 1973 +         2182 (2.6)           Seattle, 1974 +         4912 (5.9)           Utah, 1973 +         2292 (2.7)           Atlanta, 1975 +         2700 (3.2)           San Jose, 1988 +         2164 (2.6)           Los Angeles, 1988 +         7586 (9.1)           Rural Georgia, 1992 +         268 (0.3)           Greater California, 2000 +         9219 (11.0)           Kentucky, 2000 +         5418 (6.5)           Louisiana, 2000 +         4181 (5.0)           New Jersey, 2000 +         11176 (13.4)           Unknown         963 (1.2)           Histologic type         474 (0.6)           Stage at diagnosis         0, In situ           0, In situ         6913 (8.3)           I         18 624 (22.3)           II         18 822 (20.3)           Unknown         8049 (9.6)           Tumor grade         Well differentiated           Well differentiated         6750 (9.2)           Moderately differentiated         667 (0.8)           Unknown         12 931 (15.5)           Tumor size, mean (SD),	Connecticut, 1973+	8085 (9.7)
Hawaii, 1973+       1558 (1.9)         Iowa, 1973+       8863 (10.6)         New Mexico, 1973+       2182 (2.6)         Seattle, 1974+       4912 (5.9)         Utah, 1973+       2292 (2.7)         Atlanta, 1975+       2700 (3.2)         San Jose, 1988+       2164 (2.6)         Los Angeles, 1988+       7586 (9.1)         Rural Georgia, 1992+       268 (0.3)         Greater California, 2000+       9219 (11.0)         Kentucky, 2000+       5418 (6.5)         Louisiana, 2000+       4181 (5.0)         New Jersey, 2000+       11176 (13.4)         Unknown       963 (1.2)         Histologic type       4denocarcinoma         Adenocarcinoma       82 177 (98.3)         Carcinoid       974 (1.2)         Miscellaneous       474 (0.6)         Stage at diagnosis       0, In situ         0, In situ       6913 (8.3)         I       18 624 (22.3)         II       18 389 (22.0)         IV       8622 (10.3)         Unknown       8049 (9.6)         Tumor grade       Well differentiated         Well differentiated       7650 (9.2)         Moderately differentiated       49189 (58.8)	Detroit, 1973+	8443 (10.1)
lowa, 1973+         8863 (10.6)           New Mexico, 1973+         2182 (2.6)           Seattle, 1974+         4912 (5.9)           Utah, 1973+         2292 (2.7)           Atlanta, 1975+         2700 (3.2)           San Jose, 1988+         2164 (2.6)           Los Angeles, 1988+         268 (0.3)           Greater California, 2000+         9219 (11.0)           Kentucky, 2000+         4181 (5.0)           New Jersey, 2000+         4181 (5.0)           New Jersey, 2000+         11176 (13.4)           Unknown         963 (1.2)           Histologic type         4denocarcinoma           Carcinoid         974 (1.2)           Miscellaneous         474 (0.6)           Stage at diagnosis         0, In situ           0, In situ         6913 (8.3)           I         18 624 (22.3)           II         18 389 (22.0)           IV         8622 (10.3)           Unknown         8049 (9.6)           Tumor grade         Well differentiated           Well differentiated         7650 (9.2)           Moderately differentiated         49189 (58.8)           Poorly differentiated         667 (0.8)           Unknown         12 931 (15.5)	Hawaii, 1973+	1558 (1.9)
New Mexico, 1973+         2182 (2.6)           Seattle, 1974+         4912 (5.9)           Utah, 1973+         2292 (2.7)           Atlanta, 1975+         2700 (3.2)           San Jose, 1988+         2164 (2.6)           Los Angeles, 1988+         7586 (9.1)           Rural Georgia, 1992+         268 (0.3)           Greater California, 2000+         9219 (11.0)           Kentucky, 2000+         4181 (5.0)           New Jersey, 2000+         11 176 (13.4)           Unknown         963 (1.2)           Histologic type         4denocarcinoma           Adenocarcinoma         82 177 (98.3)           Carcinoid         974 (1.2)           Miscellaneous         474 (0.6)           Stage at diagnosis         0, In situ           0, In situ         6913 (8.3)           I         18 624 (22.3)           II         18 389 (22.0)           IV         8622 (10.3)           Unknown         8049 (9.6)           Tumor grade         49189 (58.8)           Poorly differentiated         7650 (9.2)           Moderately differentiated         4067 (0.8)           Unknown         12 931 (15.5)           Tumor size, mean (SD), cm         40.2 (25	Iowa, 1973+	8863 (10.6)
Seattle, 19/4+       4912 (5.9)         Utah, 1973+       2292 (2.7)         Atlanta, 1975+       2700 (3.2)         San Jose, 1988+       2164 (2.6)         Los Angeles, 1988+       7586 (9.1)         Rural Georgia, 1992+       268 (0.3)         Greater California, 2000+       9219 (11.0)         Kentucky, 2000+       4181 (5.0)         New Jersey, 2000+       11 176 (13.4)         Unknown       963 (1.2)         Histologic type       4denocarcinoma         Adenocarcinoma       82 177 (98.3)         Carcinoid       974 (1.2)         Miscellaneous       474 (0.6)         Stage at diagnosis       0, In situ         0, In situ       6913 (8.3)         I       18 624 (22.3)         II       18 389 (22.0)         IV       8622 (10.3)         Unknown       8049 (9.6)         Tumor grade       7650 (9.2)         Moderately differentiated       7650 (9.2)         Moderately differentiated       4012 (55.0)         Unknown       12 931 (15.5)         Tumor size, mean (SD), cm       40.2 (25.0)         Tumor location       21 512 (25.7)         Colon       62 113 (74.3)	New Mexico, 1973+	2182 (2.6)
Utah, 1973+       2292 (2.7)         Atlanta, 1975+       2700 (3.2)         San Jose, 1988+       2164 (2.6)         Los Angeles, 1988+       7586 (9.1)         Rural Georgia, 1992+       268 (0.3)         Greater California, 2000+       9219 (11.0)         Kentucky, 2000+       5418 (6.5)         Louisiana, 2000+       4181 (5.0)         New Jersey, 200+       11 176 (13.4)         Unknown       963 (1.2)         Histologic type       4denocarcinoma         Adenocarcinoma       82 177 (98.3)         Carcinoid       974 (1.2)         Miscellaneous       474 (0.6)         Stage at diagnosis       0, In situ         0, In situ       6913 (8.3)         I       18 624 (22.3)         II       18 389 (22.0)         IV       8622 (10.3)         Unknown       8049 (9.6)         Tumor grade       7650 (9.2)         Moderately differentiated       7650 (9.2)         Moderately differentiated       4012 (25.0)         Tumor size, mean (SD), cm       40.2 (25.0)         Tumor location       21 512 (25.7)         Colon       62 113 (74.3)         Anatomic site       21 512 (25.7) </td <td>Seattle, 1974+</td> <td>4912 (5.9)</td>	Seattle, 1974+	4912 (5.9)
Atlanta, 1975+       2700 (3.2)         San Jose, 1988+       2164 (2.6)         Los Angeles, 1988+       7586 (9.1)         Rural Georgia, 1992+       268 (0.3)         Greater California, 2000+       9219 (11.0)         Kentucky, 2000+       5418 (6.5)         Louisiana, 2000+       4181 (5.0)         New Jersey, 200+       11176 (13.4)         Unknown       963 (1.2)         Histologic type       4denocarcinoma         Adenocarcinoma       82 177 (98.3)         Carcinoid       974 (1.2)         Miscellaneous       474 (0.6)         Stage at diagnosis       0, In situ         0, In situ       6913 (8.3)         I       18 624 (22.3)         II       18 389 (22.0)         IV       8622 (10.3)         Unknown       8049 (9.6)         Tumor grade       7650 (9.2)         Moderately differentiated       7650 (9.2)         Moderately differentiated       4012 (25.0)         Tumor size, mean (SD), cm       40.2 (25.0)         Tumor location       21 512 (25.7)         Colon       62 113 (74.3)         Anatomic site       21 512 (25.7)         Distal       45 276 (54.1)	Utah, 1973+	2292 (2.7)
San Jose, 1988+       2164 (2.6)         Los Angeles, 1988+       7586 (9.1)         Rural Georgia, 1992+       268 (0.3)         Greater California, 2000+       9219 (11.0)         Kentucky, 2000+       4181 (5.0)         Louisiana, 2000+       4181 (5.0)         New Jersey, 200+       11176 (13.4)         Unknown       963 (1.2)         Histologic type       4denocarcinoma         Adenocarcinoma       82 177 (98.3)         Carcinoid       974 (1.2)         Miscellaneous       474 (0.6)         Stage at diagnosis       0, In situ         0, In situ       6913 (8.3)         I       18 624 (22.3)         III       18 389 (22.0)         IV       8622 (10.3)         Unknown       8049 (9.6)         Tumor grade       Well differentiated         Well differentiated       7650 (9.2)         Moderately differentiated       49 189 (58.8)         Poorly differentiated       467 (0.8)         Unknown       12 931 (15.5)         Tumor size, mean (SD), cm       40.2 (25.0)         Tumor location       7         Rectum       21 512 (25.7)         Colon       62 113 (74.3)      <	Atlanta, 1975+	2700 (3.2)
Los Angeles, 1988+         7586 (9.1)           Rural Georgia, 1992+         268 (0.3)           Greater California, 2000+         9219 (11.0)           Kentucky, 2000+         5418 (6.5)           Louisiana, 2000+         4181 (5.0)           New Jersey, 2000+         11176 (13.4)           Unknown         963 (1.2)           Histologic type         4denocarcinoma           Adenocarcinoma         82 177 (98.3)           Carcinoid         974 (1.2)           Miscellaneous         474 (0.6)           Stage at diagnosis         0, In situ           0, In situ         6913 (8.3)           I         18 624 (22.3)           III         18 389 (22.0)           IV         8622 (10.3)           Unknown         8049 (9.6)           Tumor grade         Well differentiated           Well differentiated         7650 (9.2)           Moderately differentiated         49 189 (58.8)           Poorly differentiated         667 (0.8)           Unknown         12 931 (15.5)           Tumor size, mean (SD), cm         40.2 (25.0)           Tumor location         7           Rectum         21 512 (25.7)           Colon         62 113 (74.3) </td <td>San Jose, 1988+</td> <td>2164 (2.6)</td>	San Jose, 1988+	2164 (2.6)
Rural Georgia, 1992+       268 (0.3)         Greater California, 2000+       9219 (11.0)         Kentucky, 2000+       5418 (6.5)         Louisiana, 2000+       4181 (5.0)         New Jersey, 2000+       11176 (13.4)         Unknown       963 (1.2)         Histologic type       4         Adenocarcinoma       82 177 (98.3)         Carcinoid       974 (1.2)         Miscellaneous       474 (0.6)         Stage at diagnosis       0, In situ         0, In situ       6913 (8.3)         I       18 624 (22.3)         II       18 389 (22.0)         IV       8622 (10.3)         Unknown       8049 (9.6)         Tumor grade       Well differentiated         Well differentiated       7650 (9.2)         Moderately differentiated       49 189 (58.8)         Poorly differentiated       491 89 (58.8)         Poorly differentiated       667 (0.8)         Unknown       12 931 (15.5)         Tumor size, mean (SD), cm       40.2 (25.0)         Tumor location       7         Rectum       21 512 (25.7)         Colon       62 113 (74.3)         Anatomic site       7         Dist	Los Angeles, 1988+	/586 (9.1)
Greater California, 2000+       9219 (11.0)         Kentucky, 2000+       5418 (6.5)         Louisiana, 2000+       4181 (5.0)         New Jersey, 2000+       11 176 (13.4)         Unknown       963 (1.2)         Histologic type       4         Adenocarcinoma       82 177 (98.3)         Carcinoid       974 (1.2)         Miscellaneous       474 (0.6)         Stage at diagnosis       0, In situ         0, In situ       6913 (8.3)         I       18 624 (22.3)         II       18 389 (22.0)         IV       8622 (10.3)         Unknown       8049 (9.6)         Tumor grade       Well differentiated         Well differentiated       7650 (9.2)         Moderately differentiated       49 189 (58.8)         Poorly differentiated       49 189 (58.8)         Poorly differentiated       667 (0.8)         Unknown       12 931 (15.5)         Tumor size, mean (SD), cm       40.2 (25.0)         Tumor location       740.2 (25.0)         Rectum       21 512 (25.7)         Colon       62 113 (74.3)         Anatomic site       71.512 (25.7)         Distal       45 276 (54.1)	Rural Georgia, 1992+	268 (0.3)
Kentucky, 2000+         5418 (6.5)           Louisiana, 2000+         4181 (5.0)           New Jersey, 2000+         11 176 (13.4)           Unknown         963 (1.2)           Histologic type         4denocarcinoma           Adenocarcinoma         82 177 (98.3)           Carcinoid         974 (1.2)           Miscellaneous         474 (0.6)           Stage at diagnosis         0, In situ           0, In situ         6913 (8.3)           I         18 624 (22.3)           II         23 028 (27.5)           III         18 389 (22.0)           IV         8622 (10.3)           Unknown         8049 (9.6)           Tumor grade         Well differentiated           Well differentiated         7650 (9.2)           Moderately differentiated         49 189 (58.8)           Poorly differentiated         49 189 (58.8)           Poorly differentiated         667 (0.8)           Unknown         12 931 (15.5)           Tumor size, mean (SD), cm         40.2 (25.0)           Tumor location         21 512 (25.7)           Colon         62 113 (74.3)           Anatomic site         21 512 (25.7)           Distal         45 276 (54.1)	Greater Galifornia, 2000+	9219 (11.0)
Louislana, 2000+         4181 (5.0)           New Jersey, 2000+         11176 (13.4)           Unknown         963 (1.2)           Histologic type         Adenocarcinoma           Adenocarcinoma         82 177 (98.3)           Carcinoid         974 (1.2)           Miscellaneous         474 (0.6)           Stage at diagnosis         0, In situ           0, In situ         6913 (8.3)           I         18 624 (22.3)           II         18 389 (22.0)           IV         8622 (10.3)           Unknown         8049 (9.6)           Tumor grade         Well differentiated           Well differentiated         7650 (9.2)           Moderately differentiated         49 189 (58.8)           Poorly differentiated         40.2 (25.0)           Tumor size, mean (SD), cm         40.2 (25.0)           Tumor location         21 512 (25.7)           Colon         62 113 (74.3)           Anatomic site         0           Distal         45 276 (54.1)           Proximal         38 349 (45.9)	Kentucky, 2000+	5418 (6.5)
New Jersey, 2000+       11176 (13.4)         Unknown       963 (1.2)         Histologic type       32177 (98.3)         Carcinoid       974 (1.2)         Miscellaneous       474 (0.6)         Stage at diagnosis       474 (0.6)         O, In situ       6913 (8.3)         I       18 624 (22.3)         II       18 624 (22.3)         II       18 389 (22.0)         IV       8622 (10.3)         Unknown       8049 (9.6)         Tumor grade       Well differentiated         Well differentiated       7650 (9.2)         Moderately differentiated       49 189 (58.8)         Poorly differentiated       49 189 (58.8)         Poorly differentiated       667 (0.8)         Unknown       12 931 (15.5)         Tumor size, mean (SD), cm       40.2 (25.0)         Tumor location       40.2 (25.0)         Rectum       21 512 (25.7)         Colon       62 113 (74.3)         Anatomic site       10         Distal       45 276 (54.1)         Proximal       38 349 (45.9)	Louisiana, 2000+	4181 (5.0)
Unknown         963 (1.2)           Histologic type         Adenocarcinoma         82 177 (98.3)           Carcinoid         974 (1.2)           Miscellaneous         474 (0.6)           Stage at diagnosis         0, In situ         6913 (8.3)           I         18 624 (22.3)           II         23 028 (27.5)           III         18 389 (22.0)           IV         8622 (10.3)           Unknown         8049 (9.6)           Tumor grade         7650 (9.2)           Moderately differentiated         7650 (9.2)           Moderately differentiated         49 189 (58.8)           Poorly differentiated         49 189 (58.8)           Poorly differentiated         667 (0.8)           Unknown         12 931 (15.5)           Tumor size, mean (SD), cm         40.2 (25.0)           Tumor location         21 512 (25.7)           Colon         62 113 (74.3)           Anatomic site         21 512 (25.7)           Distal         45 276 (54.1)           Proximal         38 349 (45.9)	New Jersey, 2000+	111/0 (13.4)
Adenocarcinoma       82 177 (98.3)         Carcinoid       974 (1.2)         Miscellaneous       474 (0.6)         Stage at diagnosis       0, In situ         0, In situ       6913 (8.3)         I       18 624 (22.3)         II       23 028 (27.5)         III       18 389 (22.0)         IV       8622 (10.3)         Unknown       8049 (9.6)         Tumor grade       7650 (9.2)         Moderately differentiated       7650 (9.2)         Moderately differentiated       49 189 (58.8)         Poorly differentiated       13 188 (15.8)         Undifferentiated       667 (0.8)         Unknown       12 931 (15.5)         Tumor size, mean (SD), cm       40.2 (25.0)         Tumor location       21 512 (25.7)         Colon       62 113 (74.3)         Anatomic site       0         Distal       45 276 (54.1)         Proximal       38 349 (45.9)	Ulikilowii Histologia type	903 (1.2)
Adenocation         32 177 (98.3)           Carcinoid         974 (1.2)           Miscellaneous         474 (0.6)           Stage at diagnosis         6913 (8.3)           0, In situ         6913 (8.3)           I         18 624 (22.3)           II         23 028 (27.5)           III         18 389 (22.0)           IV         8622 (10.3)           Unknown         8049 (9.6)           Tumor grade         7650 (9.2)           Moderately differentiated         7650 (9.2)           Moderately differentiated         49 189 (58.8)           Poorly differentiated         13 188 (15.8)           Undifferentiated         667 (0.8)           Unknown         12 2931 (15.5)           Tumor size, mean (SD), cm         40.2 (25.0)           Tumor location         21 512 (25.7)           Colon         62 113 (74.3)           Anatomic site         0           Distal         45 276 (54.1)           Proximal         38 349 (45.9)	Adapagargingma	00 177 (00 2)
Miscellaneous       974 (1.2)         Miscellaneous       474 (0.6)         Stage at diagnosis       6913 (8.3)         I       18 624 (22.3)         II       23 028 (27.5)         III       18 389 (22.0)         IV       8622 (10.3)         Unknown       8049 (9.6)         Tumor grade       7650 (9.2)         Moderately differentiated       49 189 (58.8)         Poorly differentiated       13 188 (15.8)         Unknown       12 931 (15.5)         Tumor size, mean (SD), cm       40.2 (25.0)         Tumor location       21 512 (25.7)         Colon       62 113 (74.3)         Anatomic site       0         Distal       45 276 (54.1)         Proximal       38 349 (45.9)	Caroinoid	02 177 (90.3)
Stage at diagnosis       414 (0.0)         Stage at diagnosis       6913 (8.3)         I       18 624 (22.3)         II       23 028 (27.5)         III       18 389 (22.0)         IV       8622 (10.3)         Unknown       8049 (9.6)         Tumor grade       7650 (9.2)         Moderately differentiated       49 189 (58.8)         Poorly differentiated       13 188 (15.8)         Unknown       12 931 (15.5)         Tumor size, mean (SD), cm       40.2 (25.0)         Tumor location       21 512 (25.7)         Colon       62 113 (74.3)         Anatomic site       0         Distal       45 276 (54.1)         Proximal       38 349 (45.9)	Miscellaneous	974 (1.2) 474 (0.6)
0, In situ         6913 (8.3)           I         18 624 (22.3)           II         23 028 (27.5)           III         18 389 (22.0)           IV         8622 (10.3)           Unknown         8049 (9.6)           Tumor grade         7650 (9.2)           Moderately differentiated         49 189 (58.8)           Poorly differentiated         13 188 (15.8)           Unknown         12 931 (15.5)           Tumor size, mean (SD), cm         40.2 (25.0)           Tumor location         21 512 (25.7)           Colon         62 113 (74.3)           Anatomic site         0istal         45 276 (54.1)           Proximal         38 349 (45.9)	Stage at diagnosis	474 (0.0)
o, in stud       18 624 (22.3)         I       18 624 (22.3)         II       23 028 (27.5)         III       18 389 (22.0)         IV       8622 (10.3)         Unknown       8049 (9.6)         Tumor grade       49 189 (58.8)         Poorly differentiated       49 189 (58.8)         Poorly differentiated       13 188 (15.8)         Undifferentiated       667 (0.8)         Unknown       12 931 (15.5)         Tumor size, mean (SD), cm       40.2 (25.0)         Tumor location       21 512 (25.7)         Colon       62 113 (74.3)         Anatomic site       0istal         Distal       45 276 (54.1)         Proximal       38 349 (45.9)	0 In situ	6013 (8 3)
I         23 028 (27.5)           III         18 389 (22.0)           IV         8622 (10.3)           Unknown         8049 (9.6)           Tumor grade         49 189 (58.8)           Poorly differentiated         13 188 (15.8)           Unknown         12 931 (15.5)           Tumor size, mean (SD), cm         40.2 (25.0)           Tumor location         21 512 (25.7)           Colon         62 113 (74.3)           Anatomic site         13 83 49 (45.9)	l	18 624 (22 3)
III         18 389 (22.0)           IV         8622 (10.3)           Unknown         8049 (9.6)           Tumor grade		23 028 (27 5)
In         10 600 (22.6)           IV         8622 (10.3)           Unknown         8049 (9.6)           Tumor grade         90           Well differentiated         7650 (9.2)           Moderately differentiated         49 189 (58.8)           Poorly differentiated         13 188 (15.8)           Undifferentiated         667 (0.8)           Unknown         12 931 (15.5)           Tumor size, mean (SD), cm         40.2 (25.0)           Tumor location         7           Rectum         21 512 (25.7)           Colon         62 113 (74.3)           Anatomic site         7           Distal         45 276 (54.1)           Proximal         38 349 (45.9)		18 389 (22.0)
Unknown         8049 (9.6)           Tumor grade         8049 (9.6)           Well differentiated         7650 (9.2)           Moderately differentiated         49 189 (58.8)           Poorly differentiated         13 188 (15.8)           Undifferentiated         667 (0.8)           Unknown         12 931 (15.5)           Tumor size, mean (SD), cm         40.2 (25.0)           Tumor location         7650 (9.2)           Rectum         21 512 (25.7)           Colon         62 113 (74.3)           Anatomic site         13 (74.3)           Distal         45 276 (54.1)           Proximal         38 349 (45.9)	IV	8622 (10.3)
Tumor grade         667 (6.6)           Well differentiated         7650 (9.2)           Moderately differentiated         49 189 (58.8)           Poorly differentiated         13 188 (15.8)           Undifferentiated         667 (0.8)           Unknown         12 931 (15.5)           Tumor size, mean (SD), cm         40.2 (25.0)           Tumor location         21 512 (25.7)           Colon         62 113 (74.3)           Anatomic site         0           Distal         45 276 (54.1)           Proximal         38 349 (45.9)	Unknown	8049 (9.6)
Well differentiated         7650 (9.2)           Moderately differentiated         49 189 (58.8)           Poorly differentiated         13 188 (15.8)           Undifferentiated         667 (0.8)           Unknown         12 931 (15.5)           Tumor size, mean (SD), cm         40.2 (25.0)           Tumor location         21 512 (25.7)           Colon         62 113 (74.3)           Anatomic site         0           Distal         45 276 (54.1)           Proximal         38 349 (45.9)	Tumor grade	0010(0.0)
Moderately differentiated         49 189 (58.8)           Poorly differentiated         13 188 (15.8)           Undifferentiated         667 (0.8)           Unknown         12 931 (15.5)           Tumor size, mean (SD), cm         40.2 (25.0)           Tumor location         7           Rectum         21 512 (25.7)           Colon         62 113 (74.3)           Anatomic site         1           Distal         45 276 (54.1)           Proximal         38 349 (45.9)	Well differentiated	7650 (9.2)
Poorly differentiated         13 188 (15.8)           Undifferentiated         667 (0.8)           Unknown         12 931 (15.5)           Tumor size, mean (SD), cm         40.2 (25.0)           Tumor location         21 512 (25.7)           Colon         62 113 (74.3)           Anatomic site         15tal           Distal         45 276 (54.1)           Proximal         38 349 (45.9)	Moderately differentiated	49 189 (58.8)
Undifferentiated         667 (0.8)           Unknown         12 931 (15.5)           Tumor size, mean (SD), cm         40.2 (25.0)           Tumor location         21 512 (25.7)           Colon         62 113 (74.3)           Anatomic site         10 5276 (54.1)           Proximal         38 349 (45.9)	Poorly differentiated	13 188 (15.8)
Unknown         12 931 (15.5)           Tumor size, mean (SD), cm         40.2 (25.0)           Tumor location         21 512 (25.7)           Colon         62 113 (74.3)           Anatomic site         21 512 (55.7)           Distal         45 276 (54.1)           Proximal         38 349 (45.9)	Undifferentiated	667 (0.8)
Tumor size, mean (SD), cm         40.2 (25.0)           Tumor location         21 512 (25.7)           Colon         62 113 (74.3)           Anatomic site         21 5276 (54.1)           Proximal         38 349 (45.9)	Unknown	12 931 (15.5)
Tumor location         21 512 (25.7)           Colon         62 113 (74.3)           Anatomic site         10 5276 (54.1)           Proximal         38 349 (45.9)	Tumor size, mean (SD), cm	40.2 (25.0)
Rectum         21 512 (25.7)           Colon         62 113 (74.3)           Anatomic site	Tumor location	( )
Colon         62 113 (74.3)           Anatomic site	Rectum	21 512 (25.7)
Anatomic site           Distal         45 276 (54.1)           Proximal         38 349 (45.9)	Colon	62 113 (74.3)
Distal 45 276 (54.1) Proximal 38 349 (45.9)	Anatomic site	( -)
Proximal 38 349 (45.9)	Distal	45 276 (54.1)
	Proximal	38 349 (45.9)

Abbreviations: MSA, metropolitan statistical area; PCP, primary care physician; SEER, Surveillance, Epidemiology, and End Results.

<sup>a</sup> The year with the "+" sign refers to the year when the site became part of the SEER registry (from that date to the present).

(continued)

sex, race/ethnicity, marital status at diagnosis, census-derived measures of median household income (approximate quintiles within each registry), educational levels (approximate quintiles within each registry), metropolitan statistical area, SEER geographic registry (with indicator variables for each registry), Charlson comorbidity index<sup>29</sup> (determined from both inpatient and outpatient physician claims), anatomic site (proximal vs distal lesions), and histologic cancer type (adenocarcinomas, including all subtypes, carcinoid tumors, and other). Medicare reimbursement of CRC screening occurred incrementally, with no coverage from 1994 to 1997, limited coverage between 1998 and 2000 (FOBT yearly, flexible sigmoidoscopy every 4 years, and colonoscopy only for high-risk persons), and full coverage thereafter (colonoscopy every 10 years for all persons). We therefore created indicator variables corresponding to these 3 periods and included them in the models. To account for healthy behaviors in patients seeking more primary care,<sup>30</sup> we added receipt of an influenza vaccination in the preceding 3 to 27 months as a proxy for healthy behavior.

ARCH INTERN MED/VOL 171 (NO. 19), OCT 24, 2011 WWW.ARCHINTERNMED.COM 1749

#### Table 2. Predictors of Prior Colorectal Cancer Screening Test in 83 625 Patients<sup>a</sup>

Characteristic	AOR <sup>b</sup> (95% Wald Cl)
PCP visits in previous 3-27 mo	
0 or 1	1.00 [Reference]
2-4	2.07 (1.98-2.16)
5-10	2.60 (2.48-2.72)
≥11	2.96 (2.83-3.10)
Ion-PCP visits in previous 3-27 mo	
0 or 1	1.00 [Reference]
2-4	1.57 (1.51-1.64)
5-10	1.87 (1.79-1.95)
≥11	2.74 (2.63-2.86)
Receipt of influenza vaccination in previous 3-27 mo	
No	1.00 [Reference]
Yes	1.53 (1.48-1.58)
Age at diagnosis, y	
67-75	1.00 [Reference]
76-85	1.28 (1.24-1.32)
Sex	
Male	1.00 [Reference]
Female	1.26 (1.22-1.30)
Race/ethnicity	
White, non-Hispanic	1.00 [Reference]
Black, non-Hispanic	0.96 (0.90-1.02)
Hispanic	0.79 (0.73-0.86)
Asian/American Indian/Pacific Islander	0.80 (0.74-0.86)
Other	0.92 (0.64-1.32)
Charlson comorbidity index	
0	1.00 [Reference]
1	0.95 (0.92-0.99)
≥2	0.84 (0.80-0.87)
Year of diagnosis	
1994-1997	1.00 [Reference]
1998-2000	1.41 (1.35-1.47)
2001-2005	1.22 (1.17-1.27)
Marital status	
Married, including common law	1.00 [Reference]
Single, never married	0.88 (0.83-0.93)
Separated/divorced	0.83 (0.78-0.89)
Widowed	0.87 (0.84-0.90)
Unknown	0.94 (0.87-1.02)
MSA of residence	
Large metropolitan	1.00 [Reference]
Metropolitan	0.91 (0.87-0.95)
Urban	0.98 (0.91-1.05)
Less urban	0.84 (0.78-0.91)
	0.05 (0.75.0.00)

(continued)

We examined CRC-specific mortality and all-cause mortality among persons having invasive CRC (excluding 7732 in situ cancers).<sup>8,28</sup> The association between PCP visits and CRC mortality was analyzed using Cox proportional regression models, adjusting for potential confounding factors described in the preceding paragraph in addition to tumor characteristics to control for residual confounding within each stage. To determine whether associations between PCP visits and CRC mortality were primarily the result of previous CRC screening and an earlier stage at diagnosis, models were first performed without previous CRC screening, stage at diagnosis, and tumor characteristics and then repeated including previous CRC screening, stage at diagnosis, and tumor characteristics. Similar analyses were performed to examine the relationship between PCP visits and all-cause mortality. All analyses were performed using commercial software

#### Table 2. Predictors of Prior Colorectal Cancer Screening Test in 83 625 Patients<sup>a</sup> (continued)

Characteristic	AOR <sup>b</sup> (95% Wald CI)
	(35 /8 Walu 01)
Educational level	4.00 (D.(
Quintile 1, lowest	1.00 [Reference]
Quintile 2	1.09 (1.04-1.15)
Quintile 3	1.13 (1.07-1.20)
Quintile 4	1.22 (1.15-1.29)
Quintile 5, highest	1.39 (1.29-1.49)
Income level	
Quintile 1, lowest	1.00 [Reference]
Quintile 2	0.93 (0.89-0.98)
Quintile 3	1.01 (0.95-1.06)
Quintile 4	0.96 (0.90-1.02)
Quintile 5, highest	1.01 (0.94-1.08)
SEER registry <sup>c</sup>	
San Francisco, 1973+	1.00 [Reference]
Connecticut, 1973+	1.02 (0.93-1.12)
Detroit, 1973+	0.72 (0.66-0.78)
Hawaii, 1973+	0.97 (0.84-1.12)
Iowa, 1973+	0.82 (0.74-0.91)
New Mexico, 1973+	0.60 (0.53-0.68)
Seattle, 1974+	1.02 (0.93-1.13)
Utah, 1973+	0.59 (0.52-0.67)
Atlanta, 1975+	0.92 (0.82-1.02)
San Jose, 1988+	1.02 (0.90-1.15)
Los Angeles, 1988+	0.79 (0.31-2.02)
Rural Georgia, 1992+	0.75 (0.69-0.82)
Greater California, 2000+	0.90 (0.68-1.18)
Kentucky, 2000+	0.93 (0.85-1.02)
Louisiana, 2000+	0.72 (0.65-0.80)
New Jersey, 2000+	0.52 (0.47-0.58)
Unknown	0.63 (0.58-0.68)

Abbreviations: AOR, adjusted odds ratio; MSA, Metropolitan Statistical Area; PCP, primary care physician; SEER, Surveillance, Epidemiology, and End Results.

<sup>a</sup> Ever received of fecal occult blood test, sigmoidoscopy, barium enema, or colonoscopy more than 3 months before a colorectal cancer diagnosis. <sup>b</sup> Adjusted for all other variables in the table.

<sup>c</sup> The year with the "+" sign refers to the year when the site became part of the SEER registry (from that date to the present).

(SAS version 9.2; SAS Institute, Inc, Cary, North Carolina). Data are given as mean (SD) unless otherwise indicated.

# RESULTS

**Table 1** describes our study cohort. The mean age was 75.8 (6.2) years, and most patients were non-Hispanic white. The mean number of visits to a PCP in the 3- to 27-month period before diagnosis was 7.2 (8.2), with 27.8% of the sample having 0 to 1 visit (25.0% had  $\geq$ 11 visits). The distribution of visits by specific primary care specialty was general practice, 10.6%; family medicine, 30.5%; internal medicine, 55.9%; OB/GYN, 2.2%; and geriatric medicine, 0.8%. Patients had a mean of 6.9 (9.7) visits to a non-PCP, with 34.1% having 0 to 1 visit (24.7% had  $\geq$ 11 visits).

# RECEIPT OF PREVIOUS CRC SCREENING

Overall, 38 220 persons (45.7%) had at least 1 claim of ever receiving a CRC screening test more than 3

#### Table 3. Predictors of Early-Stage Colorectal Cancer Diagnosis in 75 576 Patients<sup>a</sup>

Characteristic	AOR <sup>b</sup> (95% Wald Cl)
PCP visits in previous 3-27 mo	(00/0 1111 01)
0 or 1	1 00 [Reference]
2-4	1 22 (1 17-1 28)
5-10	1.22 (1.17 1.20)
5-10 >11	1.33(1.25-1.42) 1.41(1.25-1.48)
≤ II Non-PCP visits in previous 3-97 mo	1.41 (1.35-1.40)
0 or 1	1 00 [Reference]
2-4 5-10	$1.13(1.13^{-1.24})$ $1.29(1.23^{-1.24})$
S-10 ∽11	1.50 (1.52-1.44)
≤ II Deceipt of influenza vaccination in	1.01 (1.33-1.00)
previous 3-27 mo	
No	1.00 [Reference]
Yes	1.12 (1.08-1.15)
Age at diagnosis, y	
67-75	1.00 [Reference]
76-85	0.89 (0.86-0.92)
Sex	
Male	1.00 [Reference]
Female	0.96 (0.92-0.99)
Race/ethnicity	
White, non-Hispanic	1.00 [Reference]
Black, non-Hispanic	1.03 (0.96-1.10)
Hispanic	0.86 (0.79-0.93)
Asian/American Indian/Pacific Islander	0.94 (0.87-1.03)
Other	1.01 (0.70-1.46)
Charlson comorbidity index	· · · · ·
0	1.00 [Reference]
1	0.98 (0.94-1.02)
≥2	1.02 (0.97-1.06)
Year of diagnosis	
1994-1997	1.00 [Reference]
1998-2000	1 15 (1 10-1 21)
2001-2005	1 21 (1 16-1 26)
Marital status	
Married including common law	1 00 [Reference]
Single never married	
Senarated/divorced	0.00 (0.00 1.00)
Widowed	0.52 (0.00 0.55)
Unknown	1 53 (1 41-1 66)
MSA of residence	1.00 (1.41-1.00)
l arge metropolitan	1 00 [Reference]
Matropolitan	
Irban	1.10 (1.00-1.10)
UIDall	1.10 (1.07-1.25)
	1.09 (1.01-1.18)
UTIKITUWIT	1.16 (1.02-1.32)
Less urban Unknown	1.09 (1.01-1.18) 1.16 (1.02-1.32)

(continued)

months before the CRC diagnosis. Most claims were for FOBT (40.3%), with other services less common (office visit for CRC, 8.6%; colonoscopy, 11.8%; barium enema, 10.3%; and sigmoidoscopy, 2.0%). The likelihood of having at least 1 claim for previous CRC screening increased with increasing number of PCP visits (0 or 1 visit, 27.8%; 2-4 visits, 45.9%; 5-10 visits, 53.4%; and  $\geq$ 11 visits, 58.3%; *P*<.001 for trend). **Table 2** describes predictors of previous CRC screening. The odds of previous CRC screening increased with increasing number of PCP visits. Previous CRC screening was also independently associated with non-

#### Table 3. Predictors of Early-Stage Colorectal Cancer Diagnosis in 75 576 Patients<sup>a</sup> (continued)

Characteristic	AOR <sup>b</sup> (95% Wald Cl)
Educational level	
Quintile 1, lowest	1.00 [Reference]
Quintile 2	0.95 (0.90-1.01)
Quintile 3	0.96 (0.90-1.01)
Quintile 4	0.94 (0.89-1.01)
Quintile 5, highest	0.98 (0.91-1.06)
Income level	
Quintile 1, lowest	1.00 [Reference]
Quintile 2	1.03 (0.97-1.08)
Quintile 3	1.06 (1.00-1.12)
Quintile 4	1.03 (0.96-1.09)
Quintile 5, highest	1.06 (0.98-1.14)
SEER registry <sup>c</sup>	
San Francisco, 1973+	1.00 [Reference]
Connecticut, 1973+	1.11 (1.01-1.22)
Detroit, 1973+	0.95 (0.86-1.04)
Hawaii, 1973+	1.17 (1.00-1.36)
lowa, 1973+	0.94 (0.85-1.05)
New Mexico, 1973+	0.93 (0.81-1.06)
Seattle, 1974+	0.84 (0.76-0.94)
Utah, 1973+	0.98 (0.86-1.12)
Atlanta, 1975+	1.12 (0.99-1.26)
San Jose, 1988+	0.95 (0.84-1.08)
Los Angeles, 1988+	1.14 (1.04-1.25)
Rural Georgia, 1992+	0.76 (0.56-1.04)
Greater California, 2000+	0.98 (0.89-1.07)
Kentucky, 2000+	1.05 (0.94-1.16)
Louisiana, 2000+	1.01 (0.91-1.13)
New Jersey, 2000+	1.10 (1.00-1.20)
Unknown	0.75 (0.51-1.12)
Anatomic site	
Distal	1.00 [Reference]
Proximal	0.57 (0.55-0.59)

Abbreviations: AOR, adjusted odds ratio; MSA, Metropolitan Statistical Area; PCP, primary care physician; SEER, Surveillance, Epidemiology, and End Results.

<sup>a</sup> American Joint Commission on Cancer stages 0 and 1.

<sup>b</sup>Adjusted for all other variables in the table.

<sup>c</sup> The year with the "+" sign refers to the year when the site became part of the SEER registry (from that date to the present).

PCP visits, influenza vaccination, older age, female sex, non-Hispanic ethnicity, no comorbidity, later year of diagnosis, being married, and residing in areas with higher educational levels.

#### STAGE AT CRC DIAGNOSIS

Predictors of early stage at diagnosis (American Joint Commission on Cancer stages 0 and 1) are presented in **Table 3**. The likelihood of having early-stage CRC diagnosis increased with increasing number of PCP visits (0 or 1 visit, 29.1%; 2-4 visits, 33.2%; 5-10 visits, 36.0%; and  $\geq$ 11 visits, 37.5%; *P* < .001 for trend). Compared with persons having 0 or 1 primary care visit, those with 5 to 10 visits had 35% greater odds of receiving an earlystage CRC diagnosis. Early-stage diagnosis was also independently associated with non-PCP visits, influenza vaccination, younger age, male sex, non-Hispanic ethnicity, later year of diagnosis, and distal location of the tumor.

### Table 4. Predictors of Colorectal Cancer Mortality Among 76 712 Patients<sup>a</sup>

	HR (95% CI)			
Characteristic	Unadjusted	Multivariable Model 1 <sup>b</sup>	Multivariable Model 2 <sup>c</sup>	
PCP visits in previous 3-27 mo				
0 or 1	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]	
2-4	0.85 (0.81-0.88)	0.89 (0.85-0.92)	0.96 (0.91-1.00)	
5-10	0.79 (0.76-0.82)	0.84 (0.80-0.88)	0.94 (0.90-0.99)	
≥11	0.82 (0.78-0.85)	0.87 (0.83-0.92)	1.00 (0.95-1.05)	
Non-PCP visits in previous 3-27 mo	, , , , , , , , , , , , , , , , , , ,	х, , , , , , , , , , , , , , , , , , ,	· · · · · ·	
0 or 1	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]	
2-4	0.83 (0.80-0.87)	0.88 (0.84-0.92)	0.93 (0.89-0.97)	
5-10	0.73 (0.70-0.76)	0.78 (0.74-0.81)	0.87 (0.83-0.91)	
≥11	0.72 (0.69-0.75)	0.75 (0.72-0.79)	0.87 (0.83-0.91)	
Receipt of influenza vaccination in previous 3-27 mo	( , , , , , , , , , , , , , , , , , , ,		( , , , , , , , , , , , , , , , , , , ,	
No	1.00 [Reference]	1 00 [Reference]	1 00 [Reference]	
Yes	0 79 (0 77-0 81)	0.87 (0.84-0.90)	0.92 (0.89-0.96)	
Ane at diagnosis y				
67-75	1 00 [Reference]	1 00 [Reference]	1 00 [Reference]	
76-85	1 17 (1 14-1 21)	1 24 (1 20-1 28)	1 32 (1 28-1 36)	
Sav	1.17 (1.14 1.21)	1.24 (1.20 1.20)	1.02 (1.20 1.00)	
Malo	1.00 [Poforonco]	1 00 [Poforonco]	1 00 [Poforonco]	
Fomalo				
Rece/ethnicity	0.90 (0.95-1.01)	0.95 (0.90-0.90)	0.95 (0.91-0.90)	
	1.00 [Deference]	1.00 [Deferrence]	1 00 [Deference]	
White, non-Hispanic				
Black, non-Hispanic	1.34 (1.27-1.42)	1.23 (1.16-1.31)	1.15 (1.08-1.23)	
Hispanic Asian (Associate Indian (Basilia Islandar	1.03 (0.96-1.11)	1.00 (0.92-1.08)	0.95 (0.87-1.03)	
Asian/American Indian/Pacific Islander	0.91 (0.84-0.98)	0.92 (0.84-1.00)	0.92 (0.84-1.00)	
Other	0.92 (0.63-1.33)	0.84 (0.56-1.26)	0.73 (0.49-1.09)	
Charlson comorbidity index				
0	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]	
1	0.95 (0.91-0.98)	1.04 (1.00-1.09)	1.08 (1.04-1.13)	
≥2	1.02 (0.98-1.06)	1.18 (1.12-1.23)	1.25 (1.19-1.31)	
Year of diagnosis				
1994-1997	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]	
1998-2000	0.86 (0.83-0.90)	0.88 (0.84-0.92)	0.90 (0.86-0.93)	
2001-2005	0.57 (0.55-0.59)	0.56 (0.54-0.59)	0.70 (0.67-0.73)	
Marital status				
Married, including common law	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]	
Single, never married	1.25 (1.18-1.32)	1.14 (1.08-1.22)	1.02 (1.10-1.24)	
Separated/divorced	1.19 (1.12-1.27)	1.16 (1.08-1.24)	1.13 (1.05-1.21)	
Widowed	1.19 (1.15-1.23)	1.14 (1.09-1.18)	1.10 (1.06-1.15)	
Unknown	1.03 (0.95-1.11)	0.91 (0.83-0.99)	0.88 (0.80-0.96)	
MSA of residence				
Large metropolitan	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]	
Metropolitan	1.03 (1.00-1.07)	0.98 (0.93-1.03)	1.02 (0.97-1.08)	
Urban	1.00 (0.93-1.07)	0.94 (0.87-1.01)	0.96 (0.88-1.04)	
Less urban	1.02 (0.96-1.08)	0.94 (0.87-1.01)	0.93 (0.85-1.01)	
Unknown	1.02 (0.91-1.14)	0.93 (0.82-1.06)	0.93 (0.81-1.06)	
Educational level	, , , , , , , , , , , , , , , , , , ,	· · · · · ·	( /	
Quintile 1, lowest	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]	
Quintile 2	1 08 (1 03-1 14)	0.97 (0.92-1.02)	0.95 (0.90-1.00)	
Quintile 3	0.98 (0.94-1.03)	0.98 (0.93-1.04)	0.95 (0.89-1.01)	
Quintile 4	0.94 (0.89-0.98)	0.96 (0.90-1.02)	0.93 (0.87-0.99)	
Quintile 5 highest	0.93 (0.89-0.98)	1 00 (0.93-1.02)	0.97 (0.90-1.04)	
Income level	0.00 (0.00-0.00)	1.00 (0.30-1.07)	0.07 (0.00-1.04)	
Quintile 1 lowest	1 00 [Reference]	1 00 [Reference]	1 00 [Reference]	
Quintile 1, 10west				
	1.05(1.00-1.10)		1.00 (0.00 1.00)	
	0.90(0.92-1.01)	0.90 (0.93-1.04)	1.02 (0.90-1.08)	
Quintile 4	0.94 (0.90-0.99)	0.99 (0.93-1.05)	1.02 (0.96-1.09)	
Quintile 5, highest	0.89 (0.85-0.93)	0.93 (0.87-1.00)	0.98 (0.90-1.05)	

(continued)

When receipt of previous CRC screening was added to the model, persons having such claims were more likely to be diagnosed as having early-stage cancers (adjusted odds ratio, 1.37; 95% CI, 1.33-1.42). Controlling for previous CRC screening modestly reduced the association of PCP visits and early-stage diagnosis (0 or 1 visit: ref-

1752

#### Table 4. Predictors of Colorectal Cancer Mortality Among 76 712 Patients<sup>a</sup> (continued)

		HR (95% CI)	
Characteristic	Unadjusted	Multivariable Model 1 <sup>b</sup>	Multivariable Model 2°
SEER registry <sup>d</sup>			
San Francisco, 1973+	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]
Connecticut, 973+	0.93 (0.85-1.01)	0.95 (0.86-1.04)	0.89 (0.81-0.98)
Detroit, 1973+	1.00 (0.92-1.09)	0.98 (0.90-1.06)	0.91 (0.83-0.99)
Hawaii, 1973+	0.81 (0.71-0.93)	0.94 (0.80-1.09)	0.89 (0.76-1.05)
Iowa, 1973+	0.91 (0.84-0.99)	0.95 (0.86-1.04)	0.94 (0.85-1.04)
New Mexico, 1973+	1.11 (1.00-1.24)	1.19 (1.05-1.35)	1.11 (0.98-1.27)
Seattle, 1974+	0.94 (0.86-1.02)	0.97 (0.89-1.07)	0.92 (0.83-1.01)
Utah, 1973+	1.05 (0.94-1.17)	1.10 (0.98-1.25)	1.08 (0.95-1.22)
Atlanta, 1975+	0.98 (0.88-1.09)	0.98 (0.88-1.10)	0.94 (0.84-1.06)
San Jose, 1988+	0.90 (0.80-1.01)	0.93 (0.83-1.05)	0.90 (0.80-1.01)
Los Angeles, 1988+	0.83 (0.52-1.35)	1.00 (0.92-1.09)	0.91 (0.84-1.00)
Rural Georgia, 1992+	0.97 (0.89-1.06)	0.93 (0.71-1.22)	0.98 (0.74-1.29)
Greater California, 2000+	0.97 (0.75-1.25)	0.99 (0.90-1.09)	0.93 (0.84-1.02)
Kentucky, 2000+	0.73 (0.67-0.79)	1.19 (1.07-1.32)	1.20 (1.07-1.34)
Louisiana. 2000+	0.84 (0.77-0.93)	1.06 (0.95-1.19)	1.01 (0.89-1.13)
New Jersev. 2000+	0.80 (0.72-0.88)	1.00 (0.91-1.09)	0.92 (0.84-1.00)
Unknown	0.75 (0.69-0.82)	1 30 (0 99-1 71)	0.85 (0.64-1.12)
Tumor location			0.000 (0.01 1.1.2)
Colon	1 00 [Reference]	1 00 [Reference]	1 00 [Reference]
Bectum	1 19 (1 15-1 23)	1 18 (1 14-1 22)	1 23 (1 19-1 28)
Histologic type	1110 (1110 1120)		1.20 (1.10 1.20)
Adenocarcinoma	1 00 [Reference]		1 00 [Reference]
Carcinoid	0.48 (0.40-0.59)		0.53 (0.42-0.66)
Miscellaneous	1.35 (1.13-1.62)		0.93 (0.76-1.13)
Stane at diannosis	1.00 (1.10 1.02)		0.00 (0.70 1.10)
	1 00 [Reference]		1 00 [Reference]
, II	2 63 (2 44-2 83)		1 29 (1 18-1 40)
	6.80 (6.34-7.29)		3 54 (3 27-3 84)
IV.	32 66 (30 45-35 02)		6 47 (5 79-7 23)
Inknown	5 96 (5 52-6 44)		1 60 (1 42-1 79)
	3.30 (3.32 0.44)		1.00 (1.42 1.73)
Well differentiated	1 00 [Reference]		1 00 [Reference]
Moderately differentiated	1.58 (1.47-1.60)		
Poorly differentiated	2 76 (2 57-2 96)		1.09 (1.02-1.10)
Indifferentiated	2.10 (2.01-2.00)		1.80 (1.55-1.02)
Unknown	0.10 (2.00 <sup>-</sup> 0.00) 0.07 (0.10-0.46)		1.05 (1.05-2.24)
	2.27 (2.10-2.40)		1.00 (1.22-1.40)
Turrior Size, Cill Dravious solerastal sensor coreaning test	1.04 (1.04-1.04)		1.02 (1.02-1.03)
No	1.00 [Deference]		1.00 [Deference]
NU Vee			
162	0.77 (0.75-0.79)		0.91 (0.00-0.94)

Abbreviations: HR, hazard ratio; MSA, metropolitan statistical area; PCP, primary care physician; SEER, Surveillance, Epidemiology, and End Results. <sup>a</sup>Excludes in situ tumors.

<sup>b</sup>Model 1 is adjusted for number of PCP visits, number of non-PCP visits, influenza vaccination, age at diagnosis, sex, race/ethnicity, Charlson comorbidity index, year at diagnosis, marital status, residence, educational level, income, SEER Registry, and tumor location.

<sup>c</sup> Model 2 is adjusted for all the variables in model 1 plus histologic type, stage at diagnosis, tumor grade, tumor size, and previous colorectal cancer screening test. <sup>d</sup> The year with the "+" sign refers to the year when the site became part of the SEER registry (from that date to the present).

erence group; 2-4 visits: adjusted odds ratio, 1.16 [95% CI, 1.11-1.22]; 5-10 visits: 1.27 [1.21-1.33]; and ≥11 visits: 1.32 [1.25-1.38]).

# CRC AND ALL-CAUSE MORTALITY

Among the 76 712 persons with invasive CRC, there were 43 591 deaths overall and 16 822 deaths from CRC during the follow-up period. **Table 4** describes predictors of CRC-specific mortality. In multivariable analyses adjusting for all factors except previous CRC screening, stage at diagnosis, and tumor characteristics, the number of PCP visits was associated with lower CRC mortality. Persons with 5 to 10 PCP visits had 16% lower CRC mortality compared with the reference group. In analyses that further adjusted for CRC screening, stage at diagnosis, and tumor characteristics, 2 to 10 PCP visits remained associated with lower CRC mortality, although the relationship was attenuated.

In analyses that controlled for all covariates, 2 to 10 PCP visits were associated with reduced all-cause mortality (0 or 1 visit: reference; 2-4 visits: adjusted hazard ratio, 0.94 [95% CI, 0.91-0.97]; 5-10 visits: 0.94 [0.91-0.97]; and  $\geq$ 11 visits: 1.04 [1.01-1.07]).

Table 5. Effect of PCP Visits on Outcomes Stratified by Non-P	CP Visits	in 76712 Patients
---	-----------	-------------------

	Non-PCP Visits <sup>a</sup>			
Characteristic	0 or 1	2-4	5-10	≥11
	Adjust	ed Odds Ratio (95% CI)		
CRC screening <sup>b</sup>		. ,		
PCP visits <sup>a</sup>				
0 or 1	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]
2-4	3.55 (3.28-3.85)	2.08 (1.89-2.30)	1.84 (1.67-2.03)	1.26 (1.16-1.37)
5-10	4.70 (4.31-5.13)	2.81 (2.54-3.11)	2.18 (1.98-2.41)	1.59 (1.46-1.73)
≥11	5.35 (4.86-5.90)	3.38 (3.03-3.76)	2.62 (2.37-2.89)	1.91 (1.77-2.07)
CRC stage <sup>c</sup>	, , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , ,	· · · · ·	, , , , , , , , , , , , , , , , , , ,
PCP visits <sup>a</sup>				
0 or 1	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]
2-4	1.37 (1.27-1.47)	1.31 (1.18-1.46)	1.31 (1.18-1.46)	1.31 (1.18-1.46)
5-10	1.54 (1.42-1.68)	1.45 (1.30-1.61)	1.45 (1.30-1.61)	1.45 (1.30-1.61)
≥11	1.55 (1.41-1.71)	1.51 (1.35-1.69)	1.51 (1.35-1.69)	1.51 (1.35-1.69)
	Adjuste	d Hazard Ratio (95% CI)		
CRC mortality <sup>d</sup>				
PCP visits <sup>a</sup>				
0 or 1	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]
2-4	0.96 (0.89-1.02)	1.03 (0.93-1.14)	0.87 (0.78-0.98)	0.97 (0.88-1.08)
5-10	0.89 (0.83-0.97)	1.02 (0.92-1.14)	0.89 (0.80-1.00)	1.01 (0.91-1.12)
≥11	0.93 (0.85-1.02)	1.09 (0.97-1.22)	1.01 (0.90-1.14)	0.99 (0.90-1.09)
All-cause mortality <sup>d</sup>				
PCP visits <sup>a</sup>				
0 or 1	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]
2-4	0.94 (0.90-0.99)	0.99 (0.92-1.06)	0.91 (0.85-0.98)	0.94 (0.88-1.00)
5-10	0.89 (0.85-0.94)	0.99 (0.92-1.06)	0.93 (0.87-1.00)	0.98 (0.92-1.04)
≥11	1.01 (0.95-1.07)	1.12 (1.04-1.21)	1.05 (0.98-1.13)	1.02 (0.96-1.07)

Abbreviations: CRC, colorectal cancer; PCP, primary care physician; SEER, Surveillance, Epidemiology, and End Results.

<sup>a</sup>Number of visits in previous 3 to 27 months before the diagnosis.

<sup>b</sup>Adjusted for influenza vaccination, age at diagnosis, sex, race/ethnicity, comorbidity, year at diagnosis, marital status, residence, educational level, income level, and SEER registry.

<sup>c</sup>Adjusted for influenza vaccination, age at diagnosis, sex, race/ethnicity, comorbidity, year at diagnosis, marital status, residence, educational level, income level, SEER registry, and tumor location.

<sup>d</sup>Adjusted for influenza vaccination, age at diagnosis, sex, race/ethnicity, comorbidity, year at diagnosis, marital status, residence, educational level, income level, SEER registry, tumor location, previous CRC screening, stage, histologic type, grade, and tumor size.

# EFFECT OF PCP VISITS STRATIFIED BY NON-PCP VISITS

To disentangle the effect of PCP visits from any physician visit, we reanalyzed each outcome stratified by categories of non-PCP visits. Although 10 376 persons (12.4%) had 0 or 1 visit to both a PCP and non-PCP, there was low correlation between visits to PCPs and visits to non-PCPs (Spearman rank correlation coefficient, 0.22; P < .001). For example, 28.2% of patients with  $\geq 11$  visits to a non-PCP had 0 or 1 visit to a PCP. Among patients with 5 to 10 visits to a non-PCP, those with 5 to 10 visits to a non-PCP, those with 5 to 10 visits to a PCP had 2.18 times increased odds of previous CRC screening, 45% increased odds of early stage at diagnosis, 11% lower CRC mortality, and 7% lower all-cause mortality, compared with patients with 0 or 1 visit to a PCP (**Table 5**).

#### COMMENT

Medicare beneficiaries with CRC had better outcomes if they had more primary care utilization before diagnosis. Even within this universally insured population, 28% of Medicare beneficiaries with CRC had no or only 1 contact with PCPs in the 3 to 27 months before the diagnosis. These patients had increased risk of not ever receiving CRC screening and of having CRC of a more advanced stage, higher CRC mortality, and higher overall mortality. Although earlier CRC stage at diagnosis was associated with receipt of CRC screening,31 the association of earlier stage at diagnosis with higher utilization of primary care was not explained by receipt of CRC screening. In addition, lower CRC mortality with PCP visits was mostly, but not completely, explained by screening and earlier stage at diagnosis. The number of non-PCP visits was also associated with earlier stage and lower mortality, suggesting that access to medical care in general is important for improved CRC outcomes. However, even among patients having many visits to a non-PCP, the effect of a higher number of PCP visits on improved CRC outcomes persisted. This suggests that, regardless of the number of visits to non-PCPs, access to PCPs confers independent and additional benefits. Unfortunately, 28% of Medicare beneficiaries without a PCP report a problem finding such a physician, and 11% report a problem finding a specialist.10

This study confirms others in finding that many Medicare beneficiaries do not use the services of PCPs<sup>13</sup> and

that low primary care utilization is associated with a lack of CRC screening.32,33 However, controlling for previous CRC screening did not significantly alter the association between PCP visits and early-stage diagnosis. This suggests that factors other than CRC screening mediate the effect of PCP visits on CRC stage. For example, higher use of PCP services may lead to healthier behaviors (eg, eating less red meat, getting more exercise, not smoking, and drinking less alcohol) and use of medicines (eg, aspirin and nonsteroidal anti-inflammatory drugs) that may affect CRC stage.<sup>34-36</sup> Alternatively, findings may be explained by unmeasured patient factors, such as healthier habits in patients who seek more frequent primary care. This "healthy user effect" has been described as a potential bias in observational outcome studies whereby healthier individuals are more likely to adhere to medications or use preventive services.<sup>30</sup> As a proxy for healthy behavior, we added influenza vaccination in our models but found no appreciable change in results. We also controlled for comorbid illnesses, which were present in more patients with an increased number of visits to PCPs. In addition, we adjusted for socioeconomic status, which is correlated with overall health and health-seeking tendencies.37 However, these adjustments may not fully account for the healthy user effect.

The lower CRC mortality observed among Medicare beneficiaries with higher utilization of primary care appears to be largely the result of earlier-stage diagnosis and receipt of CRC screening. However, controlling for stage and CRC screening did not eliminate the association. This suggests that PCPs may exert influences on CRC mortality beyond CRC screening and earlier-stage diagnosis. For example, PCPs may play a role in promoting healthy behaviors and other preventive services, <sup>38</sup> managing comorbid illnesses present in a majority of patients with cancer,<sup>39</sup> and coordinating care to prevent medical, medication, and laboratory errors.<sup>40</sup> The healthy user effect may also confound the association of PCP visits with mortality. The finding that having 11 or more visits to PCPs slightly increased overall mortality may be the result of more comorbidities in these patients.

It was interesting to find a high frequency of FOBT claims compared with colonoscopy claims. Recent studies<sup>41,42</sup> in the general Medicare population have found higher use of colonoscopy than FOBT, whereas an earlier study<sup>43</sup> in Medicare patients with CRC confirms our finding that FOBT is most frequently used preceding the peridiagnostic period. One reason for the high frequency of FOBT in our study may be that we defined CRC screening as ever receiving a CRC screening test more than 3 months before diagnosis. However, even when we included only FOBT within the previous 3 to 27 months, the number of patients receiving FOBT was still almost double the number of those receiving colonoscopy. The more likely reason for our high numbers of FOBT is that we included earlier years before reimbursement and increased use of colonoscopy.

Although this research complements previous ecologic studies<sup>6-8</sup> examining PCP supply and CRC outcomes, our findings are based on observational data and therefore cannot establish causal relationships. Several potential limitations should be considered when interpreting our results. First, this study only included persons aged 67 to 85 years having Medicare fee-for-service insurance who were predominantly white, were relatively healthy, and had a relatively high mean number of physician visits. Therefore, findings may not apply to other populations. A subanalysis of persons aged 67 to 75 years (those in whom CRC screening is routinely recommended) yields even stronger associations of the number of PCP visits with CRC outcomes. We were not able to include persons in Medicare health maintenance organizations because they lack claims data. Compared with patients enrolled in Medicare health maintenance organizations, those who had Medicare fee-for-service insurance report longer and higherquality relationships with their PCPs.44 Second, our study was limited to administrative data contained within the SEER-Medicare database, which omits important patient factors (eg, healthy behaviors, severity of comorbid illness, and medication use) that may be associated with CRC stage at diagnosis or mortality. Third, we did not differentiate CRC tests according to indication (screening vs diagnostic); thus, the rate of previous CRC screening may be lower than the 45.7% found. We excluded any CRC tests performed in the 3 months before diagnosis to exclude those potentially related to the diagnosis of CRC. Fourth, our measure of primary care was limited to number of visits. We did not have detailed information on the content of visits; therefore, it is uncertain what specific aspects of the primary care visit are most important to improve CRC outcomes. We were not able to assess other core primary care attributes, such as first contact, comprehensive care, and coordinated care.45 Finally, it is uncertain whether some Medicare beneficiaries had difficulty accessing PCPs or chose to have no or limited contact with PCPs. Even relatively small ambulatory care copayments decrease the use of outpatient visits and preventive screenings.<sup>46,47</sup> Medicare's recent expansion of coverage for preventive care benefits and annual wellness visits should help emphasize the importance of PCP visits and preventive screenings.48 Further research is needed regarding how use of primary care influences CRC stage and mortality and whether our results hold true for other populations and cancers.

This study adds to the mounting evidence of the benefits of primary care in improving health outcomes<sup>49</sup> and underscores the importance of adequate access to a PCP, particularly for Medicare beneficiaries. The new health care reform law has provisions to expand primary care training programs and health insurance to all Americans<sup>11</sup>; however, reorienting the US health care system toward primary care will need more than just increasing the number of primary care trainees or expanding health insurance. Payment reforms to narrow the specialtyprimary care payment gap and reward coordination-ofcare activities of PCPs are paramount, as are capital investments to improve the primary care infrastructure and paradigm shifts in public perceptions of primary care and patient expectations.<sup>50,51</sup> Fortunately, there is a growing movement in the private and public sectors of the United States for the revitalization of primary care.<sup>52</sup> This may help strengthen the national efforts on reducing the burden of CRC.

ARCH INTERN MED/VOL 171 (NO. 19), OCT 24, 2011 WWW.ARCHINTERNMED.COM 1755

### Accepted for Publication: July 1, 2011.

Author Affiliations: Department of Family Medicine and Community Health, University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, Somerset, New Jersey, and Cancer Prevention and Control Program, Cancer Institute of New Jersey, New Brunswick (Dr Ferrante); Division of General Medicine and Primary Care, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts (Dr McCarthy); and Department of Family Medicine, University of South Florida (Drs Gonzalez, Chen, and Roetzheim and Ms Love-Jackson), and Biostatistics Division (Dr Lee), Department of Health Outcomes and Behavior (Dr Roetzheim), H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

**Correspondence:** Jeanne M. Ferrante, MD, MPH, Department of Family Medicine and Community Health, University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, 1 World's Fair Dr, Somerset, NJ 08873 (ferranjm@umdnj.edu).

Author Contributions: Dr Richard Roetzheim has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. *Study concept and design*: Ferrante, McCarthy, Gonzalez, Lee, Love-Jackson, and Roetzheim. *Acquisition of data*: Lee and Roetzheim. *Analysis and interpretation of data*: Ferrante, McCarthy, Lee, Chen, and Roetzheim. *Drafting of the manuscript*: Ferrante and Roetzheim. *Critical revision of the manuscript for important intellectual content*: Ferrante, Gonzalez, Lee, Chen, and Roetzheim. *Statistical analysis*: McCarthy, Lee, and Chen. *Obtained funding*: Roetzheim. *Administrative, technical, and material support*: Ferrante, McCarthy, Chen, Love-Jackson, and Roetzheim. *Study supervision*: Roetzheim.

Financial Disclosure: None reported.

**Funding/Support**: This study was supported by grant RSGHP-08-141-01-CPHPS from the American Cancer Society. The collection of the California cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer-reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's SEER Program under contract N01-PC-35136 awarded to the Northern California Cancer Center, contract N01-PC-35139 awarded to the University of Southern California, and contract N02-PC-15105 awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement U55/CCR921930-02 awarded to the Public Health Institute.

**Role of the Sponsor**: The funding body had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

**Disclaimer:** The interpretation and reporting of the SEER-Medicare data are the sole responsibility of the authors. The ideas and opinions expressed herein are those of the authors; endorsement by the State of California Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their contractors and subcontractors is not intended and should not be inferred. **Previous Presentations:** A portion of this study was presented as a poster at Academy Health's 2011 Annual Research Meeting; June 13, 2011; Seattle, Washington, and will also be presented at the 39th Annual Meeting of the North American Primary Care Research Group; November 15, 2011; Banff, Alberta, Canada.

Additional Contributions: The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services, Inc; and the SEER Program tumor registries in the creation of the SEER-Medicare database.

#### REFERENCES

- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300.
- US Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2008; 149(9):627-637.
- Trends Progress Report C. 2009/2010 Update. April 2010. Bethesda, MD: National Cancer Institute, NIH, DHHS. 2010. http://progressreport.cancer.gov. Accessed June 20, 2011.
- Klabunde CN, Schenck AP, Davis WW. Barriers to colorectal cancer screening among Medicare consumers. Am J Prev Med. 2006;30(4):313-319.
- Wee CC, McCarthy EP, Phillips RS. Factors associated with colon cancer screening: the role of patient factors and physician counseling. *Prev Med.* 2005;41 (1):23-29.
- Hao Y, Jemal A, Zhang X, Ward EM. Trends in colorectal cancer incidence rates by age, race/ethnicity, and indices of access to medical care, 1995-2004 (United States). *Cancer Causes Control.* 2009;20(10):1855-1863.
- Roetzheim RG, Gonzalez EC, Ramirez A, Campbell R, van Durme DJ. Primary care physician supply and colorectal cancer. J Fam Pract. 2001;50(12):1027-1031.
- Roetzheim RG, Pal N, Gonzalez EC, et al. The effects of physician supply on the early detection of colorectal cancer. J Fam Pract. 1999;48(11):850-858.
- Colwill JM, Cultice JM, Kruse RL. Will generalist physician supply meet demands of an increasing and aging population? *Health Aff (Millwood)*. 2008; 27(3):w232-w241.
- Medicare Payment Advisory Commission. Report to the Congress: Medicare Payment Policy, March 2009. Washington, DC: MedPac; 2009.
- Project HOPE—The People-to-People Health Foundation Inc. The end of the beginning: enactment of health reform. *Health Aff (Millwood)*. 2010;29(5):758-759. doi:10.1377/hlthaff.2010.0411.
- Medicare Chartbook; 2010. 4th ed. Menlo Park, CA: Kaiser Family Foundation; 2010.
- Starfield B, Chang HY, Lemke KW, Weiner JP. Ambulatory specialist use by nonhospitalized patients in US health plans: correlates and consequences. J Ambul Care Manage. 2009;32(3):216-225.
- Warren J, Klabunde C, Schrag D, Bach P, Riley G. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. *Med Care*. 2002;40(8)(suppl):VI-3-VI-18.
- Boer R, Ries L, van Ballegooijen M, Feuer EJ, Legler J, Habbema D. Ambiguities in Calculating Cancer Patient Survival: the SEER Experience for Colorectal and Prostate Cancer. Washington, DC: National Cancer Institute; 2002. Statistical Research and Applications Branch, NCI, Technical Report No. 2002-05.
- Kirschner CG, Burkett RC, Coy JA, et al; American Medical Association. *Physicians' Current Procedural Terminology: CPT '94.* Chicago, IL: American Medical Association; 1994.
- Kirschner CG, Davis SJ, Evans D, et al; American Medical Association. Current Procedural Terminology: CPT 1999. Chicago, IL: American Medical Association; 1999.
- Beebe M, Green G, Pavloski D, et al; American Medical Association. Current Procedural Terminology: CPT 2005. Chicago, IL: American Medical Association; 2004.
- Baldwin LM, Adamache W, Klabunde CN, Kenward K, Dahlman C, Warren JL. Linking physician characteristics and Medicare claims data: issues in data availability, quality, and measurement. *Med Care*. 2002;40(8)(suppl):IV-82-IV-95.
- Yu X, McBean AM, Virnig BA. Physician visits, patient comorbidities, and mammography use among elderly colorectal cancer survivors. *J Cancer Surviv*. 2007; 1(4):275-282.
- Valderas JM, Starfield B, Forrest CB, Sibbald B, Roland M. Ambulatory care provided by office-based specialists in the United States. *Ann Fam Med.* 2009; 7(2):104-111.
- 22. Gornick ME, Eggers PW, Riley GF. Associations of race, education, and patterns

of preventive service use with stage of cancer at time of diagnosis. *Health Serv Res.* 2004;39(5):1403-1427.

- Gross CP, Andersen MS, Krumholz HM, McAvay GJ, Proctor D, Tinetti ME. Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. *JAMA*. 2006;296(23):2815-2822.
- Lang K, Korn JR, Lee DW, Lines LM, Earle CC, Menzin J. Factors associated with improved survival among older colorectal cancer patients in the US: a populationbased analysis. *BMC Cancer.* 2009;9:227.
- Gonzalez EC, Ferrante JM, Van Durme DJ, Pal N, Roetzheim RG. Comorbid illness and the early detection of cancer. *South Med J.* 2001;94(9):913-920.
- HCPCS general information. Centers for Medicare & Medicaid Services Web site. https://www.cms.gov/medhcpcsgeninfo/. Accessed August 16, 2011.
- McCarthy EP, Burns RB, Coughlin SS, et al. Mammography use helps to explain differences in breast cancer stage at diagnosis between older black and white women. Ann Intern Med. 1998;128(9):729-736.
- Schonberg MA, Marcantonio ER, Ngo L, Li D, Silliman RA, McCarthy EP. Causes of death and relative survival of older women after a breast cancer diagnosis. *J Clin Oncol.* 2011;29(12):1570-1577.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40(5):373-383.
- Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. *Am J Epidemiol.* 2007;166(3):348-354.
- Fazio L, Cotterchio M, Manno M, McLaughlin J, Gallinger S. Association between colonic screening, subject characteristics, and stage of colorectal cancer. *Am J Gastroenterol.* 2005;100(11):2531-2539.
- Fenton JJ, Reid RJ, Baldwin LM, Elmore JG, Buist DS, Franks P. Influence of primary care use on population delivery of colorectal cancer screening. *Cancer Epidemiol Biomarkers Prev.* 2009;18(2):640-645.
- Cardarelli R, Thomas JE. Having a personal health care provider and receipt of colorectal cancer testing. *Ann Fam Med.* 2009;7(1):5-10.
- Wei EK, Giovannucci E, Wu K, et al. Comparison of risk factors for colon and rectal cancer. *Int J Cancer*. 2004;108(3):433-442.
- Benedetti AL, Collet JP, Boivin JF, Hanley JA. Effect of nonsteroidal antiinflammatory drugs on stage of colon cancer at diagnosis. *J Clin Epidemiol*. 2003; 56(8):782-787.
- Flossmann E, Rothwell PM; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. *Lancet*. 2007;369(9573):1603-1613.

- Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. *Ann Intern Med.* 2002; 137(4):273-284.
- Ferrante JM, Balasubramanian BA, Hudson SV, Crabtree BF. Principles of the patient-centered medical home and preventive services delivery. *Ann Fam Med.* 2010;8(2):108-116.
- Ogle KS, Swanson GM, Woods N, Azzouz F. Cancer and comorbidity: redefining chronic diseases. *Cancer*. 2000;88(3):653-663.
- Starfield B. Reinventing primary care: lessons from Canada for the United States. Health Aff (Millwood). 2010;29(5):1030-1036.
- Cooper GS, Doug Kou T. Underuse of colorectal cancer screening in a cohort of Medicare beneficiaries. *Cancer*. 2008;112(2):293-299.
- Doubeni CA, Laiyemo AO, Young AC, et al. Primary care, economic barriers to health care, and use of colorectal cancer screening tests among Medicare enrollees over time. *Ann Fam Med.* 2010;8(4):299-307.
- Cooper GS, Payes JD. Receipt of colorectal testing prior to colorectal carcinoma diagnosis. *Cancer*. 2005;103(4):696-701.
- Safran DG, Wilson IB, Rogers WH, Montgomery JE, Chang H. Primary care quality in the Medicare Program: comparing the performance of Medicare health maintenance organizations and traditional fee-for-service medicare. *Arch Intern Med.* 2002;162(7):757-765.
- Starfield B. Primary Care: Concept, Evaluation, and Policy. New York, NY: Oxford University Press; 1992.
- Trivedi AN, Moloo H, Mor V. Increased ambulatory care copayments and hospitalizations among the elderly. N Engl J Med. 2010;362(4):320-328.
- Trivedi AN, Rakowski W, Ayanian JZ. Effect of cost sharing on screening mammography in Medicare health plans. N Engl J Med. 2008;358(4):375-383.
- Hughes C. What you need to know about the Medicare preventive services expansion. *Fam Pract Manag.* 2011;18(1):22-25.
- Friedberg MW, Hussey PS, Schneider EC. Primary care: a critical review of the evidence on quality and costs of health care. *Health Aff (Millwood)*. 2010;29 (5):766-772.
- Bodenheimer T, Grumbach K, Berenson RA. A lifeline for primary care. N Engl J Med. 2009;360(26):2693-2696.
- Phillips RL Jr, Bazemore AW. Primary care and why it matters for U.S. health system reform. *Health Aff (Millwood)*. 2010;29(5):806-810.
- Grundy P, Hagan KR, Hansen JC, Grumbach K. The multi-stakeholder movement for primary care renewal and reform. *Health Aff (Millwood)*. 2010;29 (5):791-798.

# **INVITED COMMENTARY**

# The Decisive Moment

# Peril and Promise for Primary Care

The decisive moment, it is the simultaneous recognition, in a fraction of a second, of the significance of an event as well as the precise organization of forms which gives that event its proper expression. Henri Cartier-Bresson, The Decisive Moment

Health care in the United States is confronted with a "perfect storm" of unsustainable cost growth driving our national financial crisis, inadequate system performance, and the recent passage of expansive national health care reform. This is a moment of unprecedented opportunity and peril for the health care system as a whole and for primary care in particular. On one hand, the economic and health benefits of a strong primary care system are increasingly recognized as potential (if partial) solutions to our health system challenges. On the other hand, economic incentives exist that overtly encourage expensive, frequently wasteful, often uncoordinated procedural care and a resultant provider workforce heavily skewed toward specialists. Belated recognition of the extent and unsettling societal implications of this "primary care crisis"1 has led to renewed interest in innovative models of care *delivery*, such as the patientcentered medical home (PCMH),<sup>2</sup> and care *organization*, such as the accountable care organization (ACO)<sup>3</sup>—both of which require a robust base of PCPs.

Ecological correlative studies, beginning with the seminal work of Starfield et al<sup>4</sup> and others,<sup>5</sup> consistently demonstrate the relationship between PCP density and improved population health outcomes, including decreased mortality from cancer, heart disease, and stroke, as well as lower health care costs. Recent studies have attempted to refine our understanding of which components of primary care may be causally relevant in these associations. Hollander et al6 developed a measure of "attachment" of patients with specific primary care practices and showed that higher levels of such attachment were associated with lower overall health care system costs in complex, chronically ill patients. Chang et al<sup>7</sup> found that it was the number of PCPs actually providing ambulatory services-not the simple population density of physicians coded as "primary care"-that